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The MYC proto-oncogene (MYC) is one of the most frequently overexpressed genes in breast cancer that drives cancer stem cell-like
traits, resulting in aggressive disease progression and poor prognosis. In this study, we identiﬁed zinc ﬁnger transcription factor 148
(ZNF148, also called Zfp148 and ZBP-89) as a direct target of MYC. ZNF148 suppressed cell proliferation and migration and was
transcriptionally repressed by MYC in breast cancer. Depletion of ZNF148 by short hairpin RNA (shRNA) and CRISPR/Cas9 increased
triple-negative breast cancer (TNBC) cell proliferation and migration. Global transcriptome and chromatin occupancy analyses of
ZNF148 revealed a central role in inhibiting cancer cell de-differentiation and migration. Mechanistically, we identiﬁed the Inhibitor
of DNA binding 1 and 3 (ID1, ID3), drivers of cancer stemness and plasticity, as previously uncharacterized targets of transcriptional
repression by ZNF148. Silencing of ZNF148 increased the stemness and tumorigenicity in TNBC cells. These ﬁndings uncover a
previously unknown tumor suppressor role for ZNF148, and a transcriptional regulatory circuitry encompassing MYC, ZNF148, and
ID1/3 in driving cancer stem cell traits in aggressive breast cancer.
Oncogenesis (2022)11:60 ; https://doi.org/10.1038/s41389-022-00435-1

INTRODUCTION
Tumor initiation and progression often involve the dysregulation of developmentally important genes in cancer cells,
endowing them with stem cell-like features such as enhanced
self-renewal, invasiveness, and an aberrant differentiation state
[1]. Triple-negative breast cancer (TNBC) cells that lack the
expression of estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (HER2) [2],
often exhibit the molecular and functional traits of cancer stem
cells [3–9]. Despite advances in breast cancer therapy, the
survival of TNBC patients remains poor, due to aggressive cancer
progression, therapy resistance, metastasis, and recurrence,
likely due to increased cancer stemness [10]. Consequently, in
order to develop effective targeted therapy, there is a pressing
need to identify all molecular regulators that deﬁne cancer stem
cell traits in TNBC.
The MYC proto-oncogene is a transcription factor essential in
stem/progenitor cell maintenance and differentiation [11]. MYC is
frequently overexpressed in many cancers, and drives a cancer
stem cell phenotype with enhanced cell growth, metastasis, and

metabolic reprogramming [11–13]. In breast carcinomas, MYC is
one of the most frequently dysregulated oncogenes, particularly
in BRCA1-mutated, basal-like TNBCs, where MYC ampliﬁcation is
reported in up to 50% of cases [14–16]. In these cancers, the
BRCA1 gene acts as a tumor suppressor to repress the expansion
of basal stem cells and basal-like breast cancers [17–19].
We previously reported a MYC-centered regulatory network in
mouse embryonic stem (ES) cells that accounts for the similarity
between the ES cells and cancer cells, and is associated with a
worse prognosis in cancer, including cancers of the breast [20]. We
found zinc ﬁnger protein 148 (ZNF148, also called Zfp148 and
ZBP-89), a ubiquitously expressed Krüppel-like zinc ﬁnger protein,
as a target of MYC-regulatory network in mouse ES cells [20].
Partial deletion of the ZNF148 locus causes defective primordial
germ cell development in mice [21], though a complete deletion
in the C57BL/6 mouse strain leads to postnatal lethality [22]. In
malignant tumors, ZNF148 has been reported to be a suppressive
[23–25] or oncogenic [26–28] factor, depending on the tumor cell
of origins and tissue types. Despite ZNF148 being an established
node of the MYC-network in ES cells, and the signiﬁcance of MYC
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in driving cancer stem cells traits, the role of ZNF148 in breast
cancer remains elusive.
The Inhibitor of DNA binding 3 (ID3) is a member of the ID
protein family, consisting of four members (ID1 to ID4). ID1 and
ID3 share the closest sequence homology, and they are
functionally redundant [29, 30]. Developmentally, it is well
established that expression of the ID members is strongest in
stem/progenitor cells, while their levels decrease upon differentiation. However, their expression frequently becomes reactivated in
cancer, providing cancer cells with stem cell-like traits [31, 32]. In
TNBC, ID1 and ID3 are requisite for self-renewal, metastasis, tumor
re-initiation, and colonization, making them attractive targets for
cancer stem cell therapy [30, 33–35].
Herein, we provide evidence for a direct transcriptional circuitry
that functionally incorporates MYC, ZNF148, and ID1/3, regulating
cancer stem cell traits in breast cancer. MYC actively represses
ZNF148 expression, and in turn, the depletion of ZNF148 leads to
de-repression of ID1/3, which drives the cancer stem cell
phenotype. Thus, ZNF148 functions as a tumor suppressor,
promoting the differentiated state of breast cancer cells, and
suppressing cell proliferation, metastasis, and biosynthetic programs associated with cancer stem cells.
MATERIALS AND METHODS
Cell culture and In vitro clonogenic assay
MCF7, HCC1806, BT549 and MDA-MB-231 cells were cultured in RPMI-1640
(without phenol red) supplemented with 10% FCS, 2 mM Glutamine and
2% penicillin-streptomycin (P/S). HEK293T cells were cultured in DMEM
High Glucose with 10% FCS and 2% P/S. MCF10A cells were cultured in
DMEM/F12 supplemented with 5% horse serum, 20 ng/ml EGF, 100 ng/ml
cholera toxin, 0.01 mg/ml insulin and 0.5 mg/ml hydrocortisone. All cell
lines are sourced from ATCC and tested for mycoplasma contamination.
Cells were maintained at 20–80% conﬂuence at 37 °C with 5% CO2 air
atmosphere. Clonogenic assays were performed as previously described
[36]. In brief, 1 × 103 MDA-MB-231 cells were seeded into 100 mm dishes
and cultured for 12 days before cells were ﬁxed with 100% methanol for
10 min and stained with 0.5% (w/v) crystal violet in 25% methanol.

Expression constructs and oligonucleotides
The human ZNF148 cDNA was ampliﬁed from MGC clone 4423572 (GE
Healthcare Dharmacon, Inc.) and cloned into the pEF-Biotag vector [37] for
biotinylation-mediated chromatin immunoprecipitation followed by
sequencing (BioChIP-seq). The cDNA was cloned into the pLeGO-iG2
vector [38] (a gift from Boris Fehse, Addgene plasmid # 27341), for
transient transfection and stable lentivirus transduction. Oligonucleotides
used for polymerase chain reactions (PCR) are listed in Supplemental
Table 1.

Western blotting
The ZNF148-N14 rabbit polyclonal antibody was raised as previously
reported [37]. Antibodies speciﬁc for MYC (9402, Cell Signaling) and
GAPDH (sc-25778, Santa Cruz Biotechnology Inc.) were purchased
commercially. Western blotting (WB) was performed as described [37]
using 10–25 µg of nuclear protein in each lane of 4–12% Bis-Tris gels
(Invitrogen). All chemicals were purchased from Merk/Sigma-Aldrich,
unless noted otherwise.

Animal studies
All mammary orthotopic xenograft experiments were conducted in six to
eight-week-old female NOD.Cg-Prkdcscid ll2rgtm1Wjl/SzJ/Arc (NSGTM) mice
(Animal Resources Center, WA, Australia). To generate mammary tumors in
mice, 0.5 × 106 MDA-MB-231-Luc cells stably transduced with empty vector
control (EV) or ZNF148 cDNA (ZNF148OE), were resuspended in 2 mg/ml
Matrigel™-HC (BD BioSciences) and injected into inguinal mammary fat
pads of mice. To visualize the xenograft tumors in vivo, D-Luciferin (14681,
Cayman Chemical) was injected intra-peritoneally (i.p.) into mice at
150 mg/kg of body weight, 12 min before the live imaging. To minimize
the animal use, we performed power analysis using repeated-measures
ANOVA with an F test for between-within subjects with GreenhouseGeisser correction. Five mice per group provided sufﬁcient power (>0.8) to

detect an effect size of one. For imaging, randomized mice were placed
under isoﬂurane induced anesthesia and orientated ventral side down to
facilitate oxygen and isoﬂurane ﬂow through the nose cones. Images were
taken using IVIS Lumina II multispectral imaging system and analyzed with
Living Image 4.2 Software (Caliper LS, Hopkinton, MA, USA). Xenograft
experiments were not performed in a blinded manner. All experiments
involving mice were approved by the Animal Ethics Committee at Harry
Perkins Institute of Medical Research (Perth, WA, Australia).

Biotinylation-mediated chromatin immunoprecipitation
(BioChIP)
BioChIP was performed broadly as previously described [22]. MCF7 and
MDA-MB-231 cells were grown to 60–80% conﬂuence and cross-linked
with 1% formaldehyde (methanol-free) for 10 min at room temperature
and quenched with 125 mM glycine. The cells were washed and
sequentially lysed in PIPES and SDS lysis buffer. Genomic DNA was
sonicated at 4 °C with a Covaris m220 sonicator to 200 to 1000 base pair
(bp) for quantitative ChIP-PCR and 200–400 bp for BioChIP-seq. Post
immunoprecipitation, biotin-protein-DNA complexes were recovered with
Dynabeads™ M-280 Streptavidin (11205D, Thermo Fisher Scientiﬁc), before
washing and de-crosslinking and DNA puriﬁcation for subsequent
analyses.

Cellular proliferation, viability, cell cycle, and scratch wound
closure assays
MTT cell proliferation and viability assays (Roche) were performed as per
the manufacturer’s instructions. In brief, breast cancer cells were seeded
into 96-well plates at a density of 2 × 103 cells/well, cultured for 96 h before
being processed for MTT assay. Cell cycle analyses were performed on an
AccuriTM ﬂow cytometer (BD Biosciences) using the BrdU kit (BD
Biosciences) in accordance with the manufacturer’s protocol. For cell
proliferation assays using IncuCyte® live-cell imaging (Essen BioScience),
6 × 103 MDA-MB-231 and 4 × 103 BT549 cells were seeded into 96-well
plates and cultured for 100 h. For scratch wound closure assays, the cells
were cultured in IncuCyte® ImageLock 96-well plates until a monolayer
formed. The cells were serum starved 24 h prior to creating the scratch on
the cell monolayer using WoundMaker (Essen BioScience). All images and
conﬂuence measurements were performed on an IncuCyte® live-cell
imager and processed with the IncuCyte Zoom software (Essen
BioScience).

Quantitative RT-PCR and ChIP-PCR
RNA samples were prepared using RNeasy Mini Kit (QIAGEN) or SV Total
RNA Isolation system (Promega). QuantiTect Reverse Transcription Kit
(QIAGEN) was used to synthesize cDNA. Eluates from ChIP were puriﬁed
using UltraPure™ Phenol:Chloroform:Isoamyl Alcohol (25:24:1, v/v) (Invitrogen™) and ethanol precipitated using a standard protocol. Quantitative
PCR was performed on a Rotor-Gene 6000 thermocycler (Qiagen) using
SensiMixPlus SYBR (Bioline). The expression levels of genes quantiﬁed by
RT-PCR (RT-qPCR) are presented relative to that of GAPDH; while the
enrichments of regulatory regions assayed by quantitative ChIP-PCR (ChIPqPCR) were calculated relative to an unrelated region in exon 6 of the ACTB
locus, as previously described [20, 22, 39].

Transfection, RNA interference, CRISPR/Cas9, and virus
transduction
Transfection of plasmid vectors was performed using FuGENE® HD
(Promega) and Lipofectamine® 2000 transfection reagent (Thermo Fisher
Scientiﬁc) as per the manufacturer’s protocol. Stable transduction of
lentiviral short hairpin RNA (shRNA) knockdown in breast cancer cells was
performed as previously described [22]. Short hairpin RNAs (shRNAs) seed
sequences against MYC and ZNF148 are shown in Supplemental Table 2.
Retroviral transduction of pMXs-GFP and pMXs-cMYC (human) vectors was
performed essentially as previously described [37] using a pCL-10A1
packaging vector (Novus Biologicals). The CRISPR/Cas9 gRNA plasmid
targeting exon 4 of ZNF148 (Target ID: HS0000451815) was purchased
from Sigma-Aldrich.

ALDEFLUOR assay
The Aldehyde dehydrogenase (ALDH) activity in MDA-MB-231 cells was
measured using ALDEFLUORTM kit (01700, STEMCELL technologies),
following the manufacturer’s protocol. In brief, 5 × 105 cells were subjected

Oncogenesis (2022)11:60

M. Kim et al.

3

Fig. 1 MYC represses ZNF148 expression by direct chromatin occupancy. A Schematic representation of ZNF148 locus on chromosome
3q21 reverse strand. Peak calls for MYC in MCF7 (purple bars), and MCF10A (yellow bars) cells from ENCODE [47] are indicated. B Quantitative
ChIP-PCR (ChIP-qPCR) validation of MYC occupancy at −750, −2400, and −4250 bp upstream of ZNF148 promoter region in MCF7 cells
(n = 3). C As in “B” for MDA-MB-231 cells. D Analysis of MYC and ZNF148 mRNA and protein in MCF7 cells transduced with the short-hairpin
(sh) luciferase control (Ctr) and shMYC #1 and #2 lentiviruses, by RT-qPCR (top panel, n = 3) and Western blot (bottom panel). E As in “C” for
MDA-MB-231 cells. F Scatter plot of MYC and ZNF148 mRNA levels (log2) from 1904 breast cancer patient samples in METABRIC cohort [56, 78].
Spearman correlations of −0.24 (p = 5.29−27) and Pearson correlations of −0.25 (p = 1.90−27) indicate an inverse correlation of ZNF148 and
MYC mRNA levels and is depicted with a linear trend line in “red”. Student’s t-test, *P < 0.05. **P < 0.01. ***P < 0.001. ****P < 0.0001. Error bars
indicate mean ± SD.
to the ALDEFLUOR assay with 2.5 μL of activated ALDEFLUORTM reagent in
the presence or absence of 5 μL of diethylaminobenzaldehyde (DEAB).
Flow cytometry analysis was performed using AccuriTM instruments (BD
Biosciences).

Sequencing analysis
RNA-sequencing (RNA-seq) was performed on Illumina HiSeq2000 system,
and the sequenced reads were aligned to the human (GRCh38) genome
using Salmon (v.0.7.2) [40]. Differentially expressed genes (DEGs) were
determined using DEseq2 package. BioChIP-seq was performed on
NextSeq 500 and the sequenced read were mapped to human (GRCh38)
genome using Bowtie2 (v 0.5.9-r16) [41]. Peaks were called using MACS2
with a q-value cut off of 0.01 (v2.1.1) [42]. DNA binding motif analysis was
performed using HOMER [43]. Binding and Expression Target Analysis
(BETA) [44] was used to integrate and analyze BioChIP-seq and DEG data.
GREAT (v4.0.4) [45], ShinyGO (v0.61) [46] and BETA were used for gene
ontology functional annotation analysis.

Statistical analyses
Student’s t-test (two-tailed) and Two-way ANOVA (ordinary) statistical
analyses were performed using GraphPad Prism. Replicate experiments,
sample size (n), mean values, SEM, SD, or CI error bars are indicated in the
ﬁgure legends.

RESULTS
ZNF148 is repressed by MYC in breast cancer
To investigate if MYC transcriptionally regulates ZNF148 in breast
cancer, we ﬁrst examined the ChIP-seq data in the Encyclopedia of
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DNA Elements (ENCODE) database [47, 48]. Conﬁrming our
previous observation in mouse ES cells [20], MYC occupancy was
observed at the proximal promoter of ZNF148 in both MCF7 (ER
positive, luminal subtype) and MCF10A (normal-like) breast cancer
cells (Fig. 1A), and this region harbored several canonical and noncanonical E-box sequences (Supplemental Fig. 1A). To validate and
extend this observation in TNBC cells, we performed ChIP-qPCR
for MYC using MCF7 and a metastatic TNBC cell line, MDA-MB-231.
This conﬁrmed a signiﬁcant enrichment of MYC at −750 and
−4250 bp upstream regions of the ZNF148 locus (Fig. 1B, C).
Next, we performed a loss-of-function study using short hairpin
RNAs (shRNAs) against MYC to understand the impact of MYC
depletion on ZNF148 gene regulation. Two different shRNAs
signiﬁcantly reduced both MYC mRNA and protein levels in MCF7
and MDA-MB-231 cells, compared to the control samples
transduced with an shRNA targeting ﬁreﬂy luciferase (shCtr)
(Fig. 1D, E). While the majority of MYC transcriptional regulation
has been linked to gene activation [11, 12], silencing of MYC,
surprisingly resulted in increased ZNF148 mRNA and protein
expression (Fig. 1D, E). Analysis of publicly available ChIP-seq data
revealed the simultaneous presence of H3K27me3 repressive and
H3K4me3 active histone marks on the ZNF148 promoter,
consistent with a bivalent epigenetic state, suggesting the
ZNF148 gene is poised for repression and activation (Supplemental Fig. 1B). To ascertain if this negative relationship also
occurred in clinical specimens, we queried the patient-derived
gene expression data in the Molecular Taxonomy of Breast Cancer
International Consortium (METABRIC) datasets. Indeed, an inverse
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correlation between MYC and ZNF148 mRNA levels in breast
cancer patients was observed (Fig. 1F). Collectively, these results
support a direct transcriptional role for MYC in suppressing the
expression of ZNF148 in breast cancer through chromatin
occupancy.

ZNF148 suppresses breast cancer cell growth and migration
To determine the functional signiﬁcance of ZNF148 in breast
cancer, we used lentivirus to stably express ectopic ZNF148 cDNA
into ER+ breast cancer (MCF7), TNBC (MDA-MB-231, BT549, and
HCC1806), and normal-like breast (MCF10A) cell lines. RT-qPCR

Oncogenesis (2022)11:60
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Fig. 2 ZNF148 suppresses TNBC cancer cell growth and migration. A RT-qPCR analysis for ZNF148 mRNA transcripts, relative to GAPDH and
empty vector (EV) control (n = 4, top panel), and Western blot analysis for proteins (bottom panel) in MCF10A cells transduced with ZNF148
cDNA (ZNF148OE) or empty vector (EV). Incucyte cell proliferation analysis (right panel) with percentage (%) area conﬂuence on y-axis and time
(hours) on x-axis, measured by IncuCyte® live-cell imaging over 96 h period (A representative plot from n = 3 biological replicates, each with
n = 6 technical replicates, Two-way ANOVA p-values, Error bars indicate mean ± SD). B–E As in “A” for MCF7, HCC1806, BT549 and MDA-MB231 (n = 3) cells respectively. F MTT cell proliferation analysis of cells in “C–E” 96 h post cell seeding (a representative graph from n = 3
biological replicates, each with n = 10 technical repeats, Student’s t-test, Error bars indicate mean ± SEM). G BrdU cell cycle analysis of MDAMB-231-ZNF148OE and the EV control cells (n = 3). H Scratch wound healing assay of cells in “E” using IncuCyte®. (n = 3, Two-way ANOVA pvalue). I Representative images of the cells in “E” with the cell conﬂuent area depicted in purple and the initial scratch front at time 0 depicted
as a red line. Scale bars, 300 μM. J IVIS live animal imaging of NSG mice. Representative images NSG mice at 7 weeks posted engraftment of
MDA-MB-231-Luciferase cells stably transduced with empty vector control (EV) or ZNF148 cDNA (ZNF148OE) (n = 5). K Line graph with dot plot
showing biweekly average radiance values of ﬁve mice from week 1 to 9. Error bars indicate mean ± SEM. (n = 5, Two-way ANOVA p-value).
Student’s t-test, *P < 0.05. **P < 0.01. ***P < 0.001. ****P < 0.0001.

and Western blot (WB) analysis conﬁrmed the ectopic expression
of ZNF148 in these cells (Fig. 2A–E). IncuCyte cell proliferation
assay showed no change in the proliferation rate in MCF10A, but a
marginal increase in ER + MCF7 cells that stably express ectopic
ZNF148 (Fig. 2A, B). Interestingly, we observed a reduction in cell
growth in all three TNBC cell lines that overexpress ZNF148
(Fig. 2C–F). BrdU cell cycle analysis of MDA-MB-231 cells
expressing ectopic ZNF148 showed a signiﬁcant reduction in the
synthesis (S) phase as well as increased gap (G0/G1) phases
compared to the empty vector (EV) control cells, conﬁrming the
anti-proliferative effect of ZNF148 (Fig. 2G). Subsequently, the
impact of ZNF148 on cell migration in TNBC cell lines was
investigated by the IncuCyte scratch assay. To account for
ZNF148’s anti-proliferative effect, both EV controls and the
ZNF148OE cells were serum-starved for 24 h for cell cycle
synchronization prior to the migration assay. Under this synchronized state, MDA-MB-231-ZNF148OE, BT549-ZNF148OE, and
HCC1806-ZNF148OE showed signiﬁcantly slower wound closure
compared with the control (Fig. 2H, I and Supplemental Fig. 2).
The above in vitro cellular assays indicate that ZNF148 exhibits
classical tumor-suppressive traits with anti-proliferative and antimigratory effects on TNBC cells. To validate this in vivo, we
established ﬁreﬂy luciferase lentiviral expressing variants of EV
control (MDA-MB-231-Luc-EV) and ZNF148-overexpressing (MDAMB-231-Luc-ZNF148OE) cells. The established cells were xenografted into the 4th inguinal mammary fat pads of immunocompromised NSGTM mice, and tumor growth was monitored by IVIS
bioluminescence imaging. Consistent with the in vitro observations, the ZNF148-overexpressing MDA-MB-231-Luc-ZNF148OE
cells showed signiﬁcantly reduced tumor growth in mice
compared to the controls (Fig. 2J, K). Collectively, these data
support a tumor suppressive role for ZNF148 in TNBC cells.
Depletion of ZNF148 promotes breast cancer cell growth and
migration
To investigate the functional outcome of ZNF148 depletion,
CRISPR/Cas9 gRNA that targets exon 4 of ZNF148 was used to
generate a knockout clonal line MDA-MB-231-ZNF148KO that has
a complete absence of the endogenous ZNF148 protein
(Fig. 3A). The ablation of ZNF148 signiﬁcantly increased both
cell proliferation and the percentage of cells in S phase
compared to the parental control cells (Fig. 3B, C). To circumvent
potential clonal and off-target effects of the CRISPR/Cas9 gene
targeting, we complemented this assay with RNA interference of
ZNF148 by lentivirus-mediated shRNA. As expected, silencing
ZNF148 increased the cellular proliferation of both MDA-MB-231
and BT549 cells (Supplemental Fig. 3). We next performed an
IncuCyte scratch assay to investigate the role of ZNF148 in cell
migration. Under the same aforementioned serum-starved
condition, the scratch wounds closed signiﬁcantly faster in
MDA-MB-231-ZNF148KO cell cultures than in control cultures
(Fig. 3D, E), again suggesting a role for ZNF148 in inhibiting cell
migratory behavior.
Oncogenesis (2022)11:60

To determine the clinical relevance of the observed cell line
data, we examined the relapse-free survival (RFS) of breast cancer
patients based on the expression level of ZNF148. In all breast
cancer subtypes, patients with a higher level of ZNF148 had a
better survival chance, consistent with the observed tumor
suppressive and anti-migratory effect of ZNF148 (Fig. 3F). Of
particular note, improved RFS associated with high ZNF148
expression was observed only in patients with lymph nodepositive, but not in the lymph node-negative cases of breast
cancer (Fig. 3G, H). These results suggest that ZNF148’s tumor
suppressive role is more signiﬁcant in metastatic disease, which is
typically associated with the aggressive TNBC subtype.
ZNF148 restricts cellular proliferation via a transcriptional and
epigenetic mechanism
To understand the molecular basis for the tumor suppressor
activities of ZNF148, we investigated the transcriptional targets of
ZNF148. First, we introduced biotin-tagged ZNF148 into the
parental MDA-MB-231-BirA control cells expressing biotin ligase
BirA, and generated an MDA-MB-231-ZNF148Bio cell line expressing metabolically biotinylated ZNF148 (Supplemental Fig. 4). We
then employed the BioChIP-seq approach [49] to map the
genome-wide chromatin occupancy of ZNF148. Our analysis
revealed that ZNF148 occupied 12,991 genomic sites, with the
majority (56%) of the occupancy at the promoter regions, 13%
intergenic, 15% intron, and 15% in the upstream areas of genes
(Fig. 4A). The ZNF148 consensus binding sequence motif was
composed of consecutive cytosine (C) or guanine (G) repeats
(Fig. 4B). The genome-wide occupancy pattern of ZNF148 in
breast cancer was consistent with our previous observation in
hematopoietic cells [22, 39]. Moreover, the consensus DNA
binding sequence motif matched most signiﬁcantly with another
ZNF148 family member, ZNF281 (also called Zfp281 and ZBP-99)
[50], consistent with our previous ﬁndings [22]. Some of the high
scoring BioChIP-seq enrichment sites included genes that have
been implicated in cancer metastases (DDR1 [51], BMP4 [52], and
SMAD6 [53]), and cell cycle and survival (CDIP1 [54] and PPP2R5A
[55]) (Fig. 4C–E and Supplemental Fig. 5).
Gene ontology (GO) biological process term analysis of the top
1500 ZNF148 target peaks revealed chromatin organization,
covalent chromatin modiﬁcation, histone modiﬁcation, and
heterochromatin organization to be the most signiﬁcantly
enriched biological processes (Fig. 4F). In the GO cellular
component analysis, transcriptional repressor complex was the
most enriched term (Fig. 4G). Collectively, these results suggest
that ZNF148 mediates its tumor suppressor activities via a
transcriptional and epigenetic mechanism to restrict cellular
proliferation.
ZNF148 regulates cell differentiation and migration
To further illustrate the genetic program regulated by ZNF148, we
examined changes in the global transcriptomic landscape upon
silencing ZNF148 in MDA-MB-231 cells by RNA-seq. To avoid
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Fig. 3 ZNF148 depletion promotes breast cancer cell growth, migration, and a low-level associate with a worse prognosis. A Western blot
analysis of CRISPR/Cas9 ZNF148 knockout (KO) clone, compared to the wild type control (Ctr). B Percentage (%) area conﬂuence of cells in “A”,
measured by IncuCyte® live-cell imaging over 96 h period (a representative plot from n = 3 biological replicates, each with n = 6 technical
replicates, Two-way ANOVA p-value, Error bars represent mean ± SD). C BrdU cell cycle analysis of cells in “A” (n = 3, Error bars = mean ± SD).
D IncuCyte® scratch wound healing assay of cells in “A” (a representative plot from n = 3 biological replicates, each with n = 6 technical
replicates, Two-way ANOVA p-value, Error bars indicate mean ± SD, Two-way ANOVA p < 0.0001). E Representative photographs of the cells in
“A” with the cell conﬂuent area depicted in purple and the initial scratch front at time 0 depicted as a red line. Scale bars, 300 μM. F Relapsefree survival analysis of entire breast cancer patients in Kaplan–Meir plotter database [79]. G As in “F” for lymph node-positive breast cancer
cases. H As “F” for lymph node-negative cases. Student’s t-test, *P < 0.05. RFS, relapse-free survival.

potential clonal biases and allow the detection of immediate gene
expression changes, RNA-seq was performed on total RNA isolated
from early passage MDA-MB-231-shCtr and MDA-MB-231shZNF148 cells. These analyses revealed 229 signiﬁcantly upregulated genes (Padj < 0.05, Fold change > 1.5) and 298 downregulated genes (Padj < 0.05, Fold change < −1.5) upon the
depletion of ZNF148 (Fig. 5A). We identiﬁed additional direct
and indirect target genes of ZNF148 by combined analysis of
BioChIP-seq and RNA-seq data. ZNF148 occupancy was identiﬁed

in 78% of the downregulated genes, indicating that these genes
are positively regulated by ZNF148. Similarly, 59% of the genes
upregulated in MDA-MB-231-shZNF148 were the direct binding
targets of ZNF148, identifying these as negatively regulated by
ZNF148 (Fig. 5B). The plot of cumulative fraction of genes (%)
versus rank of genes based on regulatory potential score (from
high to low), predicted that ZNF148 functions as both an activator
and repressor (Fig. 5C). GO term biological process analysis of the
genes that are directly repressed by ZNF148 showed an
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Fig. 4 Genomic targets of ZNF148. A Doughnut chart showing the percentage distribution of ZNF148 chromatin occupancy peak locations
determined by BioChIP-seq. B Consensus DNA binding motif analysis of ZNF148 occupied sequences (HOMER) [43]. The top 5 representative
DNA binding sequence motifs were ranked by p-value and known transcription factors. C Representative BioChIP-seq signals at the bone
morphogenetic protein 4 (BMP4) locus in MDA-MB-231 cells expressing BirA alone or BirA and FB-ZNF148. D As in “C” for SMAD family member
6 (SMAD6) locus. E As in “C” for discoidin domain receptor tyrosine kinase 1 (DDR1) locus. F GO biological process analysis of ZNF148 top 1500
peaks. G GO cellular component analysis of ZNF148 top 1500 peaks.
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Fig. 5 Transcriptome analysis of ZNF148 knockdown cells. A Volcano plot showing 229 upregulated (>1.5 fold) genes depicted in red and
298 downregulated (<1.5 fold) genes depicted in green (Padj < 0.05). B Pie charts showing the percentage of ZNF148-bound direct target
genes or the unbound genes in up- or downregulated genes upon ZNF148 knockdown in MDA-MB-231 cells. C Transcription factor activating
and repressive function prediction by BETA [44]. The upregulated (red line) and downregulated (purple line) ZNF148 target genes are
cumulated by the rank on the basis of the regulatory potential score from high to low (X-axis). Both the up- or downregulated genes are
signiﬁcantly distributed above the non-differentially expressed static background (dashed line) by the Kolmogorov–Smirnov test [44]. D GO
biological process analysis of downregulated genes from “A”. E As in “D” for the upregulated genes.

enrichment for various macromolecule modiﬁcation, biosynthesis,
and metabolic processes, which are normally required for cell
growth (Supplemental Fig. 6B). In contrast, genes directly
activated by ZNF148 showed an enrichment for cellular component organization, organelle organization, inhibition of metabolic
process, and anatomical structure morphogenesis, which are
reminiscent of cellular differentiation processes (Supplemental Fig.
6A).
To gain further insight into the collective biological consequences of ZNF148 loss, including the direct and indirect changes,
additional GO term analysis (biological processes) was performed
on the 298 downregulated and 229 upregulated genes (Fig. 5D, E
and Supplemental Tables 3, 4). While the downregulated genes
were enriched in cytoskeleton and extracellular matrix
organization-related terms, the upregulated genes were enriched
in terms related to inhibiting development and differentiation
(Fig. 5D, E). In line with the enhanced migration phenotype
observed with the depletion of ZNF148 in vitro, we found
enrichment of cell and tissue migration GO terms (Fig. 5E). These
data collectively support the notion that ZNF148 is required for
promoting the differentiation state and suppressing metabolic
and migratory processes in breast cancer cells.
Loss of ZNF148 enhances stemness of breast cancer cells
A high level of MYC drives stemness and an aggressive phenotype
in breast cancer [11, 12, 14, 15, 56]. Based on our ﬁnding, we posit
that MYC negatively regulates ZNF148 (Fig. 1) to repress biological
processes involving cellular differentiation and development
(Fig. 5), fostering cancer stem-cell-like features in breast cancer
cells. To test our hypothesis, we measured aldehyde dehydrogenase (ALDH) enzymatic activity, which is elevated in cancer
stem cell populations [4, 5, 9]. Upon silencing ZNF148 using
shRNA, a signiﬁcant increase in the percentage of ALDH bright
(ALDHbr) cells was observed in MDA-MB-231-shZNF148, compared
with the basal level in MDA-MB-231-shCtr cells (Fig. 6A).
Consistent with this, the percentage of ALDHbr cells in MDA-MB-

231-ZNF148KO cells likewise increased signiﬁcantly compared to
the control cells (Fig. 6B). In addition, clonogenic assays, which
measure stem-like cell growth in vitro [57, 58], revealed increased
colony formation in MDA-MB-231-ZNF148KO cells compared to the
control, further validating our hypothesis that ZNF148 is a
negative regulator of stemness in breast cancer (Fig. 6C).
ZNF148 transcriptionally represses ID1 and ID3
As ZNF148 suppresses stemness in MDA-MB-231 cells, we
reasoned that certain target gene(s) of ZNF148 promoting
stemness in cancer cells, are repressed by ZNF148. To identify
downstream target gene(s) that enhance stem-like features in
breast cancer, we ranked ZNF148 ChIP-enrichment scores, and the
expression fold changes of genes within the enriched GO terms
(Fig. 5E) and identiﬁed Inhibitor of DNA binding 3 HLH protein
(ID3) as a potential candidate. ID1 and ID3 proteins are
functionally redundant and have been shown to promote breast
cancer cell self-renewal, tumor cell dissemination, and metastatic
colonization of the lung and tumor re-initiation [33–35]. Importantly, the ZNF148 occupancy was signiﬁcantly enriched at the
promoter and gene body of ID3 (Fig. 7A). A closer examination of
the other family members of ID genes, ID1, ID2, and ID4 loci, all
showed ZNF148 occupancy at the promoter and gene body,
similar to ID3, albeit statistically less signiﬁcant in MACS2 peak
calling scores (Supplemental Fig. 7). Upon silencing of ZNF148
mRNA, we observed a dramatic increase of ID3 and ID1
transcription (Fig. 7B). Conversely, the overexpression of
ZNF148 signiﬁcantly decreased ID3 and ID1 (Fig. 7C). These data
collectively provide compelling evidence that ZNF148 actively
represses ID1/3 genes in breast cancer cells.
To demonstrate the MYC-ZNF148-ID1/3 regulatory axis, we
overexpressed MYC and GFP (control) cDNA in untransformed
MCF10A breast epithelial cells using retroviruses and monitored
the changes in MYC, ZNF148, and ID1/3 transcripts. Consistent
with the repressive role of MYC on ZNF148, the MYC overexpression reduced the ZNF148 transcript level, subsequently
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Fig. 6 Loss of ZNF148 increases breast cancer cell stemness. A Representative ﬂow cytometry plots and a bar graph, showing the
percentage of viable Aldehyde dehydrogenase bright (ALDHbr) shCtr and shZNF148 MDA-MB-231 cells in the presence (+) or absence (−) of
diethylaminobenzaldehyde (DEAB) (n = 3). B As in “A” showing the percentage of ALDHbr cells in MDA-MB-231 Control and MDA-MB-231ZNF148KO cells (n = 5). C Representative image of clonogenic assay of cells in “B” stained with crystal violet (n = 3). Scale bar = 1 cm. Error bars
represent mean ± SD. Student’s t-test, *P < 0.05. SSC side scatter; ALDHbr Aldehyde dehydrogenase bright; Ctr Control; KO knockout; DEAB
diethylaminobenzaldehyde.

conveying an increase in ID3 expression (Supplemental Fig. 8A).
Next, we used lentivirus-mediated shRNA transduction to
downregulate ZNF148 in MCF10A-GFP and MCF10A-MYCOE cells
(Supplemental Fig. 8B). The ZNF148 depletion increased the
MYC transcript level in MCF10A-GFP cells, consistent with the
inverse expression correlation found in breast cancer patients
(Supplemental Figs. 8B and 1F). Furthermore, the ID3 expression
increased with the ZNF148 depletion, or with the overexpression
of MYC, while simultaneous depletion of ZNF148, and MYC
overexpression led to an additive increase in ID3 transcripts. For
ID1, the gene expression changes did not follow that of ID3
upon MYC overexpression and ZNF148 depletion, indicating an
additional layer of regulatory mechanisms in MCF10A cells.
Collectively, these data demonstrate that the genetic relationship between the MYC-ZNF148-ID3 axis is conserved across
mammary epithelial cells irrespective of their transformed
status.
Finally, we queried the METABRIC breast cancer patient data to
examine the correlation between MYC, ZNF148, and ID1/3
expression levels. Indeed, an inverse correlation between ZNF148
and both ID1/3 was observed (Fig. 7D). Furthermore, a direct
proportional expression between MYC and ID1/3 was observed
(Fig. 7E), further strengthening the existence of a MYC, ZNF148,
Oncogenesis (2022)11:60

and ID1/3 regulatory axis in controlling the stemness in breast
cancer (Fig. 7F, G).
DISCUSSION
Despite the importance of ID genes driving the cancer stem cell
phenotype in a broad array of epithelial cancers, their regulatory
mechanism remains incompletely understood. In this study, we
uncover a novel role of ZNF148 in suppressing TNBC cell growth
and metastasis and provide evidence for a direct regulatory
circuitry between MYC, ZNF148, and ID1/3 that impacts stem cell
traits in breast cancer. We show ID1 and ID3 are transcriptionally
repressed targets of ZNF148, and that silencing of ZNF148
derepresses their expression, resulting in increased stemness of
TNBC cells.
Patients with a higher level of ZNF148 show improved survival,
but interestingly, the beneﬁt of having a high ZNF148 gene
dosage is accentuated only in metastatic, lymph-node positive
disease (Fig. 3). It is possible that the effect of ZNF148 dosage in
breast cancer is more pronounced in the context of MYC,
stemness, and metastatic state of the cells. Our in vitro cell line
data suggests that the anti-proliferative effect of ZNF148 is
signiﬁcant in TNBC but not in ER+ cells (Fig. 2). MDA-MB-231, in
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Fig. 7 ZNF148 represses ID1/3. A BioChIP-seq signals at the
inhibitor of DNA binding 3 (ID3) locus in MDA-MB-231 cells
expressing BirA alone or BirA and FB-ZNF148. B RT-qPCR analysis
for ZNF148 (left panel, n = 6), ID3 (middle panel, n = 12) and ID1
(right panel, n = 6) mRNA transcripts, relative to GAPDH and
shControl (shCtr), in shZNF148 MDA-MB-231 cells. C RT-qPCR
analysis for ZNF148 (left panel, n = 6), ID3 (middle panel, n = 4)
and ID1 (right panel, n = 9) mRNA transcripts, relative to GAPDH and
empty vector (EV) control, in ZNF148 overexpressing MDA-MB-231
cells. D Scatter plots of ID3 vs. ZNF148 (Pearson r = −0.3776,
p < 0.0001), and ID1 vs. ZNF148 (Pearson r = −0.1761, p < 0.0001)
mRNA levels (log2) from 1904 breast cancer patient samples in
METABRIC cohort [56, 78]. E Scatter plot of ID3 vs MYC and ID1 vs
MYC as in “D”, with Pearson r = 0.3359 (p < 0.0001) and Pearson
r = 0.1590 (p < 0.0001) respectively, indicating a direct correlation of
ID3/1 and MYC mRNA levels. F Schematic diagram of ZNF148
actively repressing ID1/3 gene expression. G Schematic diagram of
regulatory circuitry between MYC, ZNF148, and ID1/3 in MYC-driven
stem cell-like cancer. Student’s t-test, ***P < 0.001. ****P < 0.0001.
Error bars indicate ± SD.

particular, is a highly metastatic TNBC cell line with pronounced
MYC-driven cancer stem cell features [59, 60].
Oncogenic MYC alters global transcriptional programs to drive
stem cell traits in cancer [11, 61, 62], while concomitantly
downregulating tumor suppressor genes and cell cycle regulators

[63–65]. Mechanistically, polycomb repressive complex 2 (PRC2)
has been shown to interact with MYC proteins to induce
transcriptional silencing of the target genes [66, 67]. SUZ12 and
EZH2 are core subunits of PRC2; indeed, both were enriched at the
promoter region of ZNF148 (Supplementary Fig. 1B). SUZ12 and
EZH2 occupancy, along with E-box motifs and MYC occupancy,
and H3K27me3 marks at the regulatory region of the ZNF148 locus
provide a possible mechanism for MYC-induced repression of
ZNF148 in breast cancer.
MYC also represses lineage-speciﬁc transcription factors in
mammary tissues, such as GATA3 and ESR1 to drive cancer stem
cell-like states in breast cancer [68]. We previously reported
physical interaction between ZNF148 and GATA3 proteins and
possible functional cooperation between them in hematopoietic
cells [37]. It is possible that ZNF148 may cooperate with GATA3 to
drive mammary tissue development, but without a mammaryspeciﬁc mouse knockout study, whether ZNF148 also plays a
lineage-speciﬁc transcriptional role remains unclear. Our current
study supports a role for ZNF148 as a tumor suppressor gene in
metastatic TNBC, that is actively repressed by MYC.
The level of MYC expression is exceptionally high in basal-like
TNBCs that harbor BRCA1 mutation [14–16]. The BRCA1 gene
suppressed basal stem cell expansion during mammary tumor
development [17–19] and downregulated MYC expression [69],
quenching the MYC-driven oncogenic pathways. Interestingly, the
same study identiﬁed ZNF148 as a gene signiﬁcantly upregulated
by BRCA1 [69]. Although it was not clear whether BRCA1 directly
contributed to transcriptional activation of ZNF148, the inversed
gene expression pattern between ZNF148 and MYC is consistent
with our ﬁndings. It is possible that the tumor suppression by
BRCA1 may be in part mediated by ZNF148 activation as a result
of MYC downregulation.
ZNF148 binds to GC-rich DNA motifs and shares the most
similarity with ZNF281 (Fig. 4B). We recently reported similar GCrich DNA consensus motifs, unique and overlapping chromatin
occupancy sites for ZNF148 and ZNF281, and their functional
redundancy in myelogenous leukemia cells [22]. Recently, ZNF281
was shown to activate epithelial to mesenchymal transition (EMT)
transcription factors, ZEB1 and SNAI1 via activation of the TGF-β
pathway, promoting EMT and metastasis in breast cancer [70].
Despite the similar DNA binding motifs between ZNF148 and
ZNF281, we did not observe the chromatin occupancy of ZNF148
on ZEB1 or SNAI1 loci. Moreover, contrary to the ZNF281’s prometastatic role, ectopic expression of ZNF148 inhibited cell
migration (Fig. 2H, I and Supplemental Fig. 2). ZNF281 is 80%
homologous to ZNF148 in the DNA-binding domains, but only 3
to 40% similar in the N-terminal and C-terminal domains. These
Oncogenesis (2022)11:60
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structural features may provide a foundation for shared chromatin
occupancy but a divergent role at the occupied sites. There may
be competition for occupancy at the same regulatory loci
between ZNF148 and ZNF281, but mediate different functions
by recruiting different cofactors, resulting in different net
phenotypic outcomes.
The TGF-β pathway has a dual role acting as either tumor
suppressive or oncogenic during carcinogenesis [71]. As a tumor
suppressor, TGF-β reduces the breast cancer stem cell population,
and cell proliferation via MYC, ID1, and ID3 genes [72, 73]. Given
the MYC-ZNF148-ID1/3 regulatory axis found in this study, ZNF148
may be involved in the TGF-β downstream pathways, mediating
the repression of ID1/3 genes, thus reducing the cancer stem cell
properties in breast cancer. In the breast tumor microenvironment, TGF-β is oncogenic by priming cancer cells for metastasis to
the lungs [74], facilitating the dissemination and colonization of
cancer cells that have undergone EMT via ID1 mediated
mesenchymal to epithelial transition (MET) [75]. Considering the
recent ﬁnding that ZNF281 promotes metastasis via the TGF-β
pathway, and an opposing role of ZNF148 involving MYC and ID
genes, both ZNF148 and ZNF281 may be integral transcriptional
regulators of the TGF-β pathway. Further work addressing both
ZNF148 and ZNF281 within the same cellular context will be
required to better understand the regulatory mechanisms
contributing to the cancer stem cell state and metastatic
progression.
In summary, our study adds ZNF148 to a cadre of tumor
suppressors that MYC actively represses, particularly in breast
cancer. Currently, various therapeutic approaches are being
investigated to target both MYC and the ID proteins [12, 31, 76].
Our ﬁndings suggest that upregulating ZNF148 in breast cancer
could also be beneﬁcial. Sodium butyrate, an HDAC inhibitor was
shown to increase ZNF148 expression in colorectal cancer cells
[77], however, it did not change the ZNF148 levels in breast cancer
cells (data not shown). Considering the ubiquitous nature of
ZNF148 expression, the MYC, ZNF148, ID1/3 regulatory axis may
be present in a broad array of cancers driven by MYC and ID
proteins. Future work to identify therapeutic agents that
upregulate ZNF148 could be of clinical importance, not only in
breast cancer, but in various cancers with aggressive cancer stem
cell-like traits.
DATA AVAILABILITY
The RNA-seq and BioChIP-seq data generated in this study have been deposited in
the Gene Expression Omnibus (GEO) public database under the accession numbers
GSE132953 and GSE147020, respectively.

REFERENCES
1. Visvader JE, Lindeman GJ. Cancer stem cells: Current status and evolving complexities. Cell Stem Cell. 2012;10:717–28.
2. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al.
Recommendations for human epidermal growth factor receptor 2 testing in
breast cancer: American Society of Clinical Oncology/College of American
Pathologists clinical practice guideline update. J Clin Oncol: Off J Am Soc Clin
Oncol. 2013;31:3997–4013.
3. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like
cells that self-renew, give rise to phenotypically diverse progeny and survive
chemotherapy. Breast Cancer Res: BCR. 2008;10:R25.
4. Li H, Ma F, Wang H, Lin C, Fan Y, Zhang X, et al. Stem cell marker aldehyde
dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast
cancer. Int J Biol Markers. 2013;28:e357–364.
5. Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y. Unraveling the roles of CD44/CD24
and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep.
2017;7:13856.
6. Liu M, Liu Y, Deng L, Wang D, He X, Zhou L, et al. Transcriptional proﬁles of
different states of cancer stem cells in triple-negative breast cancer. Mol Cancer.
2018;17:65.

Oncogenesis (2022)11:60

7. Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, et al. Enriched CD44(+)/CD24(−)
population drives the aggressive phenotypes presented in triple-negative breast
cancer (TNBC). Cancer Lett. 2014;353:153–9.
8. Park SY, Choi JH, Nam JS. Targeting cancer stem cells in triple-negative breast
cancer. Cancers. 2019;11:965.
9. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, et al.
Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression distribution
within intrinsic molecular subtype. J Clin Pathol. 2011;64:937–46.
10. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping
and treatment progress. Breast Cancer Res: BCR. 2020;22:61.
11. Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.
12. Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:5.
13. Murphy MJ, Wilson A, Trumpp A. More than just proliferation: Myc function in
stem cells. Trends Cell Biol. 2005;15:128–37.
14. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc ampliﬁcation in breast cancer: A
meta-analysis of its occurrence and prognostic relevance. Br J Cancer.
2000;83:1688–95.
15. Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, Ridderstrale KK, et al.
MYC is ampliﬁed in BRCA1-associated breast cancers. Clin Cancer Res: Off J Am
Assoc Cancer Res. 2004;10:499–507.
16. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape
of somatic mutations in 560 breast cancer whole-genome sequences. Nature.
2016;534:47–54.
17. Bai F, Chan HL, Scott A, Smith MD, Fan C, Herschkowitz JI, et al. BRCA1 suppresses
epithelial-to-mesenchymal transition and stem cell dedifferentiation during
mammary and tumor development. Cancer Res. 2014;74:6161–72.
18. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in
BRCA1 mutation carriers. Nat Med. 2009;15:907–13.
19. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, et al.
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and
not from basal stem cells. Cell Stem Cell. 2010;7:403–17.
20. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, et al. A Myc network accounts
for similarities between embryonic stem and cancer cell transcription programs.
Cell. 2010;143:313–24.
21. Takeuchi A, Mishina Y, Miyaishi O, Kojima E, Hasegawa T, Isobe K. Heterozygosity
with respect to Zfp148 causes complete loss of fetal germ cells during mouse
embryogenesis. Nat Genet. 2003;33:172–6.
22. Woo AJ, Patry CA, Ghamari A, Pregernig G, Yuan D, Zheng K, et al. Zfp281 (ZBP99) plays a functionally redundant role with Zfp148 (ZBP-89) during erythroid
development. Blood Adv. 2019;3:2499–511.
23. Gao XH, Liu QZ, Chang W, Xu XD, Du Y, Han Y, et al. Expression of ZNF148 in
different developing stages of colorectal cancer and its prognostic value: a large
Chinese study based on tissue microarray. Cancer. 2013;119:2212–22.
24. Wang N, Li MY, Liu Y, Yu J, Ren J, Zheng Z, et al. ZBP-89 negatively regulates selfrenewal of liver cancer stem cells via suppression of Notch1 signaling pathway.
Cancer Lett. 2020;472:70–80.
25. Zhang CZ, Cao Y, Yun JP, Chen GG, Lai PB. Increased expression of ZBP-89 and its
prognostic signiﬁcance in hepatocellular carcinoma. Histopathology.
2012;60:1114–24.
26. Cai MY, Luo RZ, Li YH, Dong P, Zhang ZL, Zhou FJ, et al. High-expression of ZBP89 correlates with distal metastasis and poor prognosis of patients in clear cell
renal cell carcinoma. Biochem Biophys Res Commun. 2012;426:636–42.
27. Essien BE, Sundaresan S, Ocadiz-Ruiz R, Chavis A, Tsao AC, Tessier AJ, et al.
Transcription factor ZBP-89 drives a feedforward loop of beta-catenin expression
in colorectal cancer. Cancer Res. 2016;76:6877–87.
28. Yan SM, Wu HN, He F, Hu XP, Zhang ZY, Huang MY, et al. High expression of zincbinding protein-89 predicts decreased survival in esophageal squamous cell
cancer. Ann Thorac Surg. 2014;97:1966–73.
29. de Candia P, Benera R, Solit DB. A role for Id proteins in mammary gland physiology and tumorigenesis. Adv Cancer Res. 2004;92:81–94.
30. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O’Reilly R, et al. Id1 and Id3 are
required for neurogenesis, angiogenesis, and vascularization of tumour xenografts. Nature. 1999;401:670–7.
31. Lasorella A, Benezra R, Iavarone A. The ID proteins: Master regulators of cancer
stem cells and tumour aggressiveness. Nat Rev Cancer. 2014;14:77–91.
32. Roschger C, Cabrele C. The Id-protein family in developmental and cancerassociated pathways. Cell Commun Signal. 2017;15:7.
33. Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K, et al. ID
genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl
Acad Sci USA. 2007;104:19506–11.
34. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate
breast cancer metastasis to lung. Nature. 2005;436:518–24.

M. Kim et al.

12
35. Teo WS, Holliday H, Karthikeyan N, Cazet AS, Roden DL, Harvey K, et al. Id proteins
promote a cancer stem cell phenotype in mouse models of triple negative breast
cancer via negative regulation of Robo1. Front Cell Dev Biol. 2020;8:552.
36. Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay
of cells in vitro. Nat Protoc. 2006;1:2315–9.
37. Woo AJ, Moran TB, Schindler YL, Choe SK, Langer NB, Sullivan MR, et al. Identiﬁcation of ZBP-89 as a novel GATA-1-associated transcription factor involved in
megakaryocytic and erythroid development. Mol Cell Biol. 2008;28:2675–89.
38. Weber K, Bartsch U, Stocking C, Fehse B. A multicolor panel of novel lentiviral
“gene ontology” (LeGO) vectors for functional gene analysis. Mol Ther.
2008;16:698–706.
39. Woo AJ, Kim J, Xu J, Huang H, Cantor AB. Role of ZBP-89 in human globin gene
regulation and erythroid differentiation. Blood. 2011;118:3684–93.
40. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and
bias-aware quantiﬁcation of transcript expression. Nat Methods. 2017;14:417–9.
41. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat
Methods. 2012;9:357–9.
42. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Modelbased analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.
43. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements
required for macrophage and B cell identities. Mol Cell. 2010;38:576–89.
44. Wang S, Sun H, Ma J, Zang C, Wang C, Wang J, et al. Target analysis by
integration of transcriptome and ChIP-seq data with BETA. Nat Protoc.
2013;8:2502–15.
45. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT
improves functional interpretation of cis-regulatory regions. Nat Biotechnol.
2010;28:495–501.
46. Ge SX, Son EW, Yao R. iDEP: An integrated web application for differential
expression and pathway analysis of RNA-Seq data. BMC Bioinform. 2018;19:534.
47. Consortium EP. An integrated encyclopedia of DNA elements in the human
genome. Nature. 2012;489:57–74.
48. Davis CA, Hitz BC, Sloan CA, Chan ET, Davidson JM, Gabdank I, et al. The Encyclopedia of DNA elements (ENCODE): Data portal update. Nucleic Acids Res.
2018;46:D794–D801.
49. Kim J, Cantor AB, Orkin SH, Wang J. Use of in vivo biotinylation to study
protein–protein and protein–DNA interactions in mouse embryonic stem cells.
Nat Protoc. 2009;4:506–17.
50. Fidalgo M, Huang X, Guallar D, Sanchez-Priego C, Valdes VJ, Saunders A, et al.
Zfp281 coordinates opposing functions of Tet1 and Tet2 in pluripotent states.
Cell Stem Cell. 2016;19:355–69.
51. Hou G, Vogel WF, Bendeck MP. Tyrosine kinase activity of discoidin domain
receptor 1 is necessary for smooth muscle cell migration and matrix metalloproteinase expression. Circulation Res. 2002;90:1147–9.
52. Choi S, Yu J, Park A, Dubon MJ, Do J, Kim Y, et al. BMP-4 enhances epithelial
mesenchymal transition and cancer stem cell properties of breast cancer cells via
Notch signaling. Sci Rep. 2019;9:11724.
53. de Boeck M, Cui C, Mulder AA, Jost CR, Ikeno S, ten Dijke P. Smad6 determines
BMP-regulated invasive behaviour of breast cancer cells in a zebraﬁsh xenograft
model. Sci Rep. 2016;6:24968.
54. Inukai R, Mori K, Kuwata K, Suzuki C, Maki M, Takahara T, et al. The novel ALG-2
target protein CDIP1 promotes cell death by interacting with ESCRT-I and VAPA/
B. Int J Mol Sci. 2021;22:1175
55. Qiu Z, Fa P, Liu T, Prasad CB, Ma S, Hong Z, et al. A genome-wide pooled shRNA
screen identiﬁes PPP2R2A as a predictive biomarker for the response to ATR and
CHK1 inhibitors. Cancer Res. 2020;80:3305–18.
56. Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, et al. The
somatic mutation proﬁles of 2,433 breast cancers reﬁnes their genomic and
transcriptomic landscapes. Nat Commun. 2016;7:11479.
57. Li X, Wang H, Yang X, Wang X, Zhao L, Zou L, et al. GABRP sustains the stemness
of triple-negative breast cancer cells through EGFR signaling. Cancer Lett.
2021;514:90–102.
58. Zhao L, Qiu T, Jiang D, Xu H, Zou L, Yang Q, et al. SGCE promotes breast cancer
stem cells by stabilizing EGFR. Adv Sci. 2020;7:1903700.
59. Gupta N, Jung K, Wu C, Alshareef A, Alqahtani H, Damaraju S, et al. High Myc
expression and transcription activity underlies intra-tumoral heterogeneity in
triple-negative breast cancer. Oncotarget. 2017;8:28101–15.
60. Reynolds DS, Tevis KM, Blessing WA, Colson YL, Zaman MH, Grinstaff MW. Breast
cancer spheroids reveal a differential cancer stem cell response to chemotherapeutic treatment. Sci Rep. 2017;7:10382.
61. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb
Perspect Med. 2013;3:a014217.
62. Yang A, Qin S, Schulte BA, Ethier SP, Tew KD, Wang GY. MYC inhibition depletes
cancer stem-like cells in triple-negative breast cancer. Cancer Res.
2017;77:6641–50.

63. Gartel AL, Shchors K. Mechanisms of c-myc-mediated transcriptional repression
of growth arrest genes. Exp Cell Res. 2003;283:17–21.
64. Pietenpol JA, Holt JT, Stein RW, Moses HL. Transforming growth factor beta
1 suppression of c-myc gene transcription: Role in inhibition of keratinocyte
proliferation. Proc Natl Acad Sci USA. 1990;87:3758–62.
65. Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massague J. TGFbeta
inﬂuences Myc, Miz-1, and Smad to control the CDK inhibitor p15INK4b. Nat Cell
Biol. 2001;3:400–8.
66. Corvetta D, Chayka O, Gherardi S, D’Acunto CW, Cantilena S, Valli E, et al. Physical
interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2)
in neuroblastoma: Functional and therapeutic implications. J Biol Chem.
2013;288:8332–41.
67. Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, et al. N-Myc induces
an EZH2-mediated transcriptional program driving neuroendocrine prostate
cancer. Cancer Cell. 2016;30:563–77.
68. Poli V, Fagnocchi L, Fasciani A, Cherubini A, Mazzoleni S, Ferrillo S, et al. MYCdriven epigenetic reprogramming favors the onset of tumorigenesis by inducing
a stem cell-like state. Nat Commun. 2018;9:1024.
69. Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher
EM, et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA. 2002;99:7560–5.
70. Ji W, Mu Q, Liu XY, Cao XC, Yu Y. ZNF281-miR-543 feedback loop regulates
transforming growth factor-beta-induced breast cancer metastasis. Mol Ther
Nucleic Acids. 2020;21:98–107.
71. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, et al. TGF-beta switches
from tumor suppressor to prometastatic factor in a model of breast cancer
progression. J Clin Investig. 2003;112:1116–24.
72. Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to stress
signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell. 2003;11:915–26.
73. Tang B, Yoo N, Vu M, Mamura M, Nam JS, Ooshima A, et al. Transforming growth
factor-beta can suppress tumorigenesis through effects on the putative cancer
stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res. 2007;67:8643–52.
74. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, et al. TGFbeta primes
breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell.
2008;133:66–77.
75. Stankic M, Pavlovic S, Chin Y, Brogi E, Padua D, Norton L, et al. TGF-beta-Id1
signaling opposes Twist1 and promotes metastatic colonization via a
mesenchymal-to-epithelial transition. Cell Rep. 2013;5:1228–42.
76. Wang E, Sorolla A, Cunningham PT, Bogdawa HM, Beck S, Golden E, et al. Tumor
penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy
for triple-negative breast cancers. Oncogene. 2019;38:140–50.
77. Bai L, Merchant JL. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human
cells. J Biol Chem. 2000;275:30725–33.
78. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The
genomic and transcriptomic architecture of 2000 breast tumours reveals novel
subgroups. Nature. 2012;486:346–52.
79. Gyorffy B. Survival analysis across the entire transcriptome identiﬁes biomarkers
with the highest prognostic power in breast cancer. Comput Struct Biotechnol J.
2021;19:4101–9.

ACKNOWLEDGEMENTS
The authors acknowledge the facilities, and the scientiﬁc and technical assistance of
the National Imaging Facility at the Center for Microscopy, Characterization &
Analysis, The University of Western Australia, a facility funded by the University, State
and Commonwealth Governments. AJW is supported by the Royal Perth Hospital
Medical Research Foundation, Cancer Council of Western Australia (WA), Department
of Health, Government of WA, and Walk for Women’s Cancer Gift. Breast cancer
research in JW laboratory was supported by Department of Defense (BC200469).

AUTHOR CONTRIBUTIONS
Conceptualization: AJW; methodology, AJW, LE, DCV, JYW, and JK; investigation, AJW,
MK, B-KL, MH, KR, MS, and LW; animal ethics, AJW, KR, and LMS; funding acquisition,
AJW, PB, JW, JK, and PJL; writing – ﬁrst draft, AJW; writing – review & editing, MK, JK,
DCV, LE, JW, PB, and PJL; supervision, AJW and PJL.

COMPETING INTERESTS
The authors declare no competing interests.

Oncogenesis (2022)11:60

M. Kim et al.

13
ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41389-022-00435-1.
Correspondence and requests for materials should be addressed to Peter J.
Leedman or Andrew J. Woo.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://
creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

Oncogenesis (2022)11:60

